LogicBio Therapeutics IncChange company Symbol lookupSelect an option...LOGC LogicBio Therapeutics IncOSUR OraSure Technologies IncKMI Kinder Morgan IncRSG Republic Services IncTGEN Tecogen IncEPAM Epam Systems IncISLE Isleworth Healthcare Acquisition CorpTRMD Torm PLCTHC Tenet Healthcare CorpBKCC BlackRock Capital Investment CorpGo
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
LogicBio Therapeutics, Inc. is a clinical-stage genetic medicine company. It is focused on genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. Its genome editing platform, GeneRide, is an approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid repair process, potentially to durable therapeutic protein expression levels. Its gene delivery platform, sAAVy, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate, LB-001 is developed for the treatment of methylmalonic acidemia (MMA) in pediatric patients. LB-001 is designed to introduce a functional copy of the methylmalonyl-CoA mutase (MUT) gene into the genome of MMA patients. It is developing LB-401 for the treatment of hereditary tyrosinemia type 1. It is also developing LB-301 for the treatment of Crigler-Najjar syndrome (CN).
|
|
|
|
| |
Upcoming Events
Past Earnings
GAAP vs. Non-GAAP Earnings
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
| Date | Event description | Earnings per share actual | Earnings estimate range | Previous year's actual |
|---|---|---|---|---|
| May 16, 2022 | Q1 2022 Earnings Release | -$0.20 | -$0.32 to -$0.26 | -$0.32 |
| March 4, 2022 | Q4 2021 Earnings Release | -$0.28 | -$0.38 to -$0.30 | -$0.22 |
| November 15, 2021 | Q3 2021 Earnings Release | -$0.31 | -$0.39 to -$0.05 | -$0.34 |
| August 9, 2021 | Q2 2021 Earnings Release | -$0.33 | -$0.39 to -$0.01 | -$0.35 |
Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.
, , , Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.